National Health Partners Inc. (NHPR)
Chiropractors use hands-on spinal manipulation and other alternative treatments, the theory being that proper alignment of the body's musculoskeletal structure, particularly the spine, will enable the body to heal itself without surgery or medication. Manipulation is used to restore mobility to joints restricted by tissue injury caused by a traumatic event, such as falling, or repetitive stress, such as sitting without proper back support.
Chiropractic treatment for back pain is used to address musculoskeletal conditions, such as problems with the muscles, joints, bones, and connective tissue. Research studies on this treatment have been of uneven quality and insufficient findings to allow firm conclusions. Nonetheless, the general sense is that chiropractic back pain treatment and conventional medical treatments are likely equally helpful, at least when it comes to lower back pain.
Healthcare focuses on the relationship between the body's structure, primarily the spine, and function. Doctors of chiropractic medicine, who are also called chiropractors or chiropractic physicians, use a type of hands-on therapy called manipulation or adjustment as their core clinical procedure.
National Health Partners, Inc Choose from over 12,000 chiropractors nationwide who offer a FREE spinal exam plus savings of 50% on diagnostic tests and x-rays and 30% on adjustments and treatments. There are no limitations on the number of treatments received per year.
Need medical assistance in the middle of the night? Need healthcare advise on your children or elderly parents? Need detailed information on specific health conditions? Here is the answer. Experienced RNs offer information 24 hours a day to assist you in making the correct choice for your health situation, i.e., minor health situations, medications, treatment options and self-care tips. Plus, access 2,200 topics (including 600 in Spanish) by phone or on-line, plus printed copies also available from the audio health information library or obtain information on-line including reference/research data, news articles, and live sessions or set up your own personal health profile. The 24-Hour Nurseline can assist you with the following plus more: Aging, AIDS, Allergies, Alzheimer's, Arthritis, Back Pain, Bones, Cancer, Child Health, Circulation, Common Illnesses, Coronary Disease, Cosmetic Surgery, Dental, Diabetes, Emergencies, Fitness, Foot Care, General Health, Infectious Diseases, Medications, Migraines, Nervous System, Smoking, Sleep Problems, Vision, and Weight Control.
National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called "CARExpress." CARExpress is one of the largest networks of hospitals, doctors, sdentists, pharmacists and other healthcare providers in the country and is comprised of over 1,000,000 medical professionals that belong to such PPOs as CareMark and Aetna. The company's primary target customer group is the 47 million Americans who have no health insurance of any kind. The company's secondary target customer group includes the millions of Americans who lack complete health insurance coverage.
National Health Partners, Inc., a leading provider of discount healthcare membership programs, announced the recent signing of two new significant marketing agreements. These two clients provide very different opportunities and continue to expand the reach of CARExpress into new marketplaces.
By launching their own unique internet marketing program, the first group should be able to provide a widespread push into the on-line market to produce an excellent volume of new CARExpress sales into the pipeline. In addition, the second group offers a reach into the wholesale marketplace where CARExpress will be wrapped into other programs to enhance the value of the overall package to the consumer. We would consider this non-traditional business and a great opportunity to expand our reach as well as recognition of the CARExpress program nationwide.
The company plans to announce the rollout of these new marketing campaigns as well as several others over the next few weeks.
For more information please visit official website of NHPR: www.nationalhealthpartners.com
**********************************************************
AngioDynamics Inc. (Nasdaq:ANGO) a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that it will report its fiscal 2011 fourth quarter and full year financial results on Thursday, July 14, 2011, after the close of the U.S. financial markets. Scott Solano, AngioDynamics' interim Chief Executive Officer, and Joseph Gersuk, Executive Vice President and Chief Financial Officer, will host an investment community conference call beginning at 4:30 p.m. Eastern Time on July 14, 2011, to discuss the results and to answer questions.
AngioDynamics, Inc. designs, develops, manufactures, and markets various therapeutic and diagnostic devices that enable interventional physicians to treat peripheral vascular disease, tumors, and other non-coronary diseases. It operates in three segments: Peripheral Vascular, Access, and Oncology/Surgery.
**********************************************************
Pharmaceutical Product Development Inc. (Nasdaq:PPDI) announced it has appointed Edward Ian as vice president of clinical development for Asia Pacific. Mr. Ian will be based in Singapore and will provide strategic leadership and operational oversight for PPD's Phase II-IV business in the region. "Edward Ian brings more than 15 years of clinical operations, central laboratory management, quality management systems and project management expertise through his long tenure with multinational companies in Asia Pacific and the United States," said Paul Colvin, executive vice president of global clinical development at PPD. "His expertise across a wide range of areas within the clinical research industry will play a significant role in advancing our strong position in this growing region."
Pharmaceutical Product Development, Inc., a contract research organization, provides drug discovery, development, and lifecycle management services. It operates in two segments, Development and Laboratory Services. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
**********************************************************
China Natural Gas, Inc. (Nasdaq:CHNG) announced that he entered into an exclusivity agreement with a consortium backed by Themes Investment Partners, a China-focused private equity firm. Mr. Ji informed the Special Committee of the Board of Directors of the Company (the "Special Committee") that he intended to work together with the consortium to formulate a proposal to acquire all of the outstanding shares of common stock of China Natural Gas he and his affiliates do not currently own through a going private transaction at a proposed price of $4.25 per share in cash. Mr. Ji, directly and indirectly, currently beneficially owns approximately 13.99% of the Company's common stock.
China Natural Gas, Inc. engages in the distribution and sale of natural gas and gasoline to commercial, industrial, and residential customers in the Peoples' Republic of China. China Natural Gas, Inc. was incorporated in 1999 and is headquartered in Xian, the People's Republic of China.
**********************************************************
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced that it is presenting new data from its ALN-TTR program at the 2011 Peripheral Nerve Society Meeting being held in Potomac, Maryland. The company is reporting results from a natural history study which was designed to measure blood levels of wild-type and mutant transthyretin (TTR) over time in both transthyretin-mediated amyloidosis (ATTR) patients and gene carriers. The study was performed at Boston Medical Center under the direction of John Berk, M.D., who leads the Amyloid Clinical Program at Boston University School of Medicine. ALN-TTR01 is currently in a Phase I clinical trial for the treatment of ATTR.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi). The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at http://crwepicks.com/disclaimer ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings, Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings, Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 3,000,000 shares of (144) restricted common stock from the company and 3,000,000 shares of free trading shares from a third party (PIERRE BESUCHET) for six months of advertisement services for National Health Partners Inc. (NHPR.OB).
Source: http://crweblayne.posterous.com/nhpr-ango-ppdi-chng-alny-ango-stocks-to-watch
toronto blue jays toronto blue jays ashley judd viggo mortensen combat arms gonorrhea cake boss
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.